November's issue of the Alimentary Pharmacology & Therapeutics reviews coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease.
Coffee consumption may modulate the risk of the metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD).
Dr Yilmaz and colleagues from Turkey reviewed the experimental, epidemiological and clinical studies investigating the association between coffee consumption and the risk of MetS and NAFLD.
A literature search was conducted with the aim of finding original experimental, epidemiological and clinical articles on the association between coffee consumption, MetS and NAFLD.
The team searched PubMed, Embase, Scopus and Science Direct.
 |
| 4 of 6 studies reported an inverse association between coffee and the risk of MetS |
| Alimentary Pharmacology & Therapeutics |
The team found that 3 experimental animal studies investigated the effects of coffee in the MetS, whereas 5 examined whether experimental coffee intake may modulate the risk of fatty liver infiltration.
All of the animal studies showed a protective effect of coffee towards the development of MetS and NAFLD.
Moreover, the team identified 11 epidemiological and clinical studies that met the inclusion criteria.
Of them, 6 were carried out on the risk of the MetS, and 5 on the risk of NAFLD.
The research team noted that 4 of the 6 studies reported an inverse association between coffee consumption and the risk of MetS.
The 2 studies showing negative results were from the same study cohort consisting of young persons with a low prevalence of the MetS.
The team found that all of the epidemiological and clinical studies on NAFLD reported a protective effect of coffee intake.
Dr Yilmaz's team commented, "Coffee intake can reduce the risk of NAFLD."
"Whether this effect may be mediated by certain components of the MetS deserves further investigation."
Aliment Pharmacol Ther 2013: 38(9): 1038–1044
15 October 2013
No comments:
Post a Comment